Risk & Crisis Management Latin America company information, Employees & Contact Information

BCR-ABL: The molecular mastermind behind chronic myeloid leukemia ScienceDirect.com

The Evolution of Tyrosine Kinase Inhibitor Therapy: Improving Outcomes in Patients with Newly Diagnosed Chronic Myelogenous Leukemia Journal of Hematology Oncology Pharmacy

Stathmin-2 enhances motor axon regeneration after injury independent of its binding to tubulin PNAS

Synergistic lethality in chronic myeloid leukemia – targeting oxidative phosphorylation and unfolded protein response effectively complements tyrosine kinase inhibitor treatment BMC Cancer

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia The New England Journal of Medicine

What is Chronic Myeloid Leukemia (CML)? Moffitt

Impact of emerging ACA on survival in chronic myeloid leukemia (CML) Nature

Epigenetic Reprogramming and Emerging Epigenetic Therapies in CML Frontiers

What is Chronic Myeloid Leukemia (CML)? Symptoms, Risk Factors & Treatments MD Anderson Cancer Center

Stopping TKI Treatment Is Safe, Improves Quality of Life for Some with CML National Cancer Institute (.gov)

Discontinuation of CML Therapy: Which Patients Are Ideal Candidates? The ASCO Post

Granulocyte–Macrophage Progenitors as Candidate Leukemic Stem Cells in Blast-Crisis CML The New England Journal of Medicine

Impact of frontline treatment approach on outcomes of myeloid blast phase CML Journal of Hematology & Oncology

A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9 PNAS

Altered Microenvironmental Regulation of Leukemic and Normal Stem Cells in Chronic Myelogenous Leukemia ScienceDirect.com

Glutathione determines chronic myeloid leukemia vulnerability to an inhibitor of CMPK and TMPK Nature

Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia The New England Journal of Medicine

Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia The New England Journal of Medicine

Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia The New England Journal of Medicine

Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia The New England Journal of Medicine

Fact or Fiction: Chronic Myelogenous Leukemia (CML) Medscape Reference

Nilotinib Can Be Discontinued in Some Patients with Chronic Myelogenous Leukemia National Cancer Institute (.gov)

Application of artificial intelligence in chronic myeloid leukemia (CML) disease prediction and management: a scoping review BMC Cancer

Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation Nature

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia The New England Journal of Medicine

Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate ScienceDirect.com

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia The New England Journal of Medicine

Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia The New England Journal of Medicine

Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL The New England Journal of Medicine

CML derived exosomes promote tumor favorable functional performance in T cells BMC Cancer

Metabolic alterations mediated by STAT3 promotes drug persistence in CML Nature

New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib Resistance ACP Journals

Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring Wiley Online Library

Genetic separation of chronic myeloid leukemia stem cells from normal hematopoietic stem cells at single-cell resolution Nature

Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome The New England Journal of Medicine

CML Clinical Trials and Latest Treatment Options Healthline

Chronic Myeloid Leukemia The New England Journal of Medicine

Oncogenic CSF3R Mutations in Chronic Neutrophilic Leukemia and Atypical CML The New England Journal of Medicine

What to know about CML remission Medical News Today

About CML European Environment Agency (EEA)

Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias The New England Journal of Medicine

Complete Molecular Remission in Chronic Myelogenous Leukemia after Imatinib Therapy The New England Journal of Medicine

CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy Nature

Magic Bullets in Medicine: Rethinking the Approach Clarivate

DIPP seeks details on blood cancer drug for issuance of CL Mint